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Meconium aspiration syndrome (MAS) is a common cause of severe respiratory distress in term infants, with an associated
highly variable morbidity and mortality. MAS results from aspiration of meconium during intrauterine gasping or during the
ﬁrst few breaths. The pathophysiology of MAS is multifactorial and includes acute airway obstruction, surfactant dysfunction
or inactivation, chemical pneumonitis with release of vasoconstrictive and inﬂammatory mediators, and persistent pulmonary
hypertension of newborn (PPHN). This disorder can be life threatening, often complicated by respiratory failure, pulmonary
air leaks, and PPHN. Approaches to the prevention of MAS have changed over time with collaboration between obstetricians
and pediatricians forming the foundations for care. The use of surfactant and inhaled nitric oxide (iNO) has led to the decreased
mortalityandtheneedforextracorporealmembraneoxygenation(ECMO)use.Inthispaper,wereviewthecurrentunderstanding
of the pathophysiology and management of MAS.
1.Introduction
Meconium aspiration syndrome (MAS) is deﬁned as res-
piratory distress in an infant born through meconium-
stained amniotic ﬂuid (MSAF) with characteristic radio-
logical changes and whose symptoms cannot be otherwise
explained [1]. Because meconium is rarely found in the
amniotic ﬂuid prior to 34 weeks’ gestation, MAS is often a
disease of the term and near-term infant and is associated
with signiﬁcant respiratory morbidity and mortality. Cleary
and Wiswell [2] have proposed a severity criteria to deﬁne
MAS: (a) mild MAS is a disease that requires less than 40%
oxygen for less than 48 hours, (b) moderate MAS is a disease
that requires more than 40% oxygen for more than 48 hours
with no air leak, and (c) severe MAS is a disease that requires
assisted ventilation for more than 48 hours and is often
associated with PPHN. In this paper, we look at the current
understandingofthepathogenesisandmanagementofMAS.
2. Epidemiology of MAS
Meconium is a viscous sticky dark green substance con-
taining gastrointestinal secretions, bile, bile acids, mucus,
pancreatic juice, blood, swallowed vernix caseosa, lanugo,
and cellular debris. Intrauterine hypoxia may cause passage
of meconium in the amniotic ﬂuid. MSAF is present in 8–
20% of all deliveries [1–4], increasing to 23–52% after 42
weeks of gestation [5, 6]. Meconium aspiration may occur
before birth, or during the birth process. About 2–9% of
infants born through MSAF develop MAS [7–9]. About one-
thirdofinfantswithMASrequireintubationandmechanical
ventilation [9].
Factors that promote the passage of meconium in
utero include placental insuﬃciency, maternal hypertension,
preeclampsia, oligohydramnios, and maternal drug abuse,
especially of tobacco and cocaine. The risk of MAS is
increased in black Americans, Africans, and Paciﬁc Islanders
[7, 10]. Factors associated with the development of MAS
among infants with MSAF include thicker consistency of
meconium, nonreassuring fetal heart tracing, fetal acidosis,
cesarean delivery, meconium below the cords, infants who
needed intubation at birth, and a low Apgar score [9, 11].
In the United States, the incidence of MAS decreased nearly
fourfold from 5.8% to 1.5% between 1990–1992 and 1997-
1998 and this was attributed to a 33% reduction in births
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of nonreassuring fetal heart rate patterns, and greater use
of amnioinfusion [12]. MAS remains a serious problem in
developing and newly industrialized countries, and MAS
accounts for about 10% of all cases of respiratory failure with
39% mortality rate [13].
3.Pathophysiology ofMAS
MAS results from aspiration of meconium during intrauter-
ine gasping or during the ﬁrst few breaths. Fetal hypoxic
stress can stimulate colonic activity, resulting in the passage
of meconium and also stimulates fetal gasping movements
that result in meconium aspiration in-utero. Mounting
evidence suggests that a chronic in utero insult may be
responsible for most cases of severe MAS as opposed to an
acute peripartum event [14, 15].
The pathophysiology of MAS is complex. Aspirated
meconium can interfere with normal breathing by several
mechanisms. The pathophysiologic mechanisms of hypox-
emia in MAS include (a) acute airway obstruction, (b)
surfactant dysfunction or inactivation, (c) chemical pneu-
monitis with release of vasoconstrictive and inﬂammatory
mediators, and (d) PPHN with right-to-left extrapulmonary
shunting. The common disturbances of lung function in
MAS include hypoxemia and decreased lung compliance.
Poor oxygenation is attributed to a combination of ven-
tilation perfusion mismatching, intrapulmonary shunting
related to regional atelectasis and extrapulmonary shunting
related to PPHN.
Depending on the consistency and amount of meconium
aspirated, meconium may lead to either partial or complete
airway obstruction leading to hyperinﬂation or atelectasis
of the alveoli. The gas trapped may rupture resulting in air
leak syndromes such as pulmonary interstitial emphysema,
pneumothorax, and pneumomediatinum.
Presence of meconium in the alveoli can inactivate
the endogenous surfactant and decrease the production of
surfactant proteins A and B [16, 17]. This causes atelectasis
of the lung and can increase ventilation perfusion mismatch.
The exact mechanisms for meconium-induced inactivation
of pulmonary surfactant are not clearly understood. How-
ever,severalcomponentsofmeconium,especiallyfat-soluble
(free fatty acids, cholesterol, and triglycerides), and water-
soluble (containing bilirubin, bile acids, enzymes, etc.) ones
impairlungfunction[17].Meconiumcanimpairpulmonary
surfactant by a combined action of cholesterol and bile
acid present in meconium [18]. Meconium may also change
the viscosity and ultrastructure of the surfactant, decrease
the levels of surfactant proteins, and also accelerate the
conversion from large, surface active aggregates into small,
less active forms. The surfactant dysfunction is enhanced
by leakage of plasma protein through an injured alveolar-
capillary membrane, as well as the proteolytic enzymes, and
oxygen-free radical release from activated cells during the
inﬂammation.
Meconium can cause chemical pneumonitis. Meconium
is a good chemoattractant for neutrophils [19]. Within a few
hours, neutrophils and macrophages are found in the alveoli,
larger airways, and lung parenchyma. Meconium is also a
source of proinﬂammatory mediators such as interleukins
(IL-1, IL 6, and IL 8), tumor necrosis factors. Thus it may
induceinﬂammationeitherdirectlyorindirectlythroughthe
stimulation of oxidative bursts in neutrophils and alveolar
macrophages and may injure the lung parenchyma or lead to
vascularleakage causing toxic pneumonitis and hemorrhagic
pulmonary edema [2].
Acute intrapulmonary meconium contamination indu-
ces a concentration-dependent pulmonary hypertensive re-
sponse, with 15–20% of infants with the MAS showing
PPHN. PPHN in infants with MAS may be caused by
(a) pulmonary vasoconstriction secondary to hypoxia,
hypercarbia, and acidosis, (b) hypertrophy of the postacinar
capillaries as a result of chronic intrauterine hypoxia, and
(c) pulmonary vasoconstriction as a result of pulmonary
inﬂammation.
Despite the fact that meconium itself has detrimental
eﬀects on placental and umbilical tissues in utero, very
little is known regarding the meconium-stimulated cellular
and biochemical alterations in ﬂuid-ﬁlled fetal lungs [20].
However, heavy meconium staining is supposed to inhibit,
through unknown mechanisms, fetal lung ﬂuid reabsorption
at birth that may disturb the ability of the lungs to adapt
properly to extrauterine life [21].
The extent of lung destruction is not closely correlated
to the quantity of meconium in lung tissue but rather to
the degree of hypoxia and acidosis present at delivery [22].
GhidiniandSpongpostulatedthatsevereMASmaynotbein
factcausallyrelatedtotheaspirationofmeconiumbutrather
caused by other pathologic processes occurring in utero,
such as chronic asphyxia, infection, or persistent pulmonary
hypertension [15].
4.DiagnosisofMAS
It is important to monitor infants born through MSAF
for any signs of respiratory distress for at least 24 hours.
Diagnosis of MAS is based on the presence of respiratory
distress in an infant born through MSAF, with no alternate
cause for respiratory distress. Chest radiograph and blood
gas analysis should be performed if necessary. Because
of diverse mechanisms causing this disease, radiographic
ﬁndings are diﬀerent. The classic radiographic ﬁndings in
MAS are overexpansion of the lungs with widespread coarse,
patchy inﬁltrates. However, the severity of the X-ray pattern
does not always correlate with the clinical picture. The lack
of correlation between clinical severity and radiographic
pattern suggests that MAS is less dependent on the amount
of meconium obstruction and parenchymal damage than on
other aspects of MAS, such as the presence and severity of
PPHN.
5. Management of MAS
5.1. Prevention of MAS. The decrease in the incidence of
MAS in the last decade has been attributed to the reduction
in postterm delivery, aggressive management of abnormal
heart rate monitoring, and decreased number of infants with
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5.1.1. Antepartum Period. Meta-analysis of 14 randomized
controlled trials (RCTs) suggests that elective induction of
labor for pregnancies at or beyond 41 weeks is associated
with signiﬁcant reduction in the incidence of MAS (RR =
0.43, 95% CI 0.23–0.79) and fewer perinatal deaths (RR =
0.31; 95% CI: 0.11–0.88) compared to expectant manage-
ment [23].
5.1.2. Intrapartum Fetal Monitoring. Intrapartum monitor-
ing has been recommended to screen for early signs of fetal
hypoxia, a risk factor for MAS. There is no evidence that
electronic fetal heart rate monitoring (EFM) with or without
fetal blood gas and acid-based assessment reduces the risk
of fetal or neonatal mortality or morbidity [24]. Fetal scalp
pH determination and newer modes like fetal pulse oximetry
will improve decision making in timing of delivery and may
reduce the incidence of MSAF and MAS [25].
5.1.3. Amnioinfusion. Amnioinfusion has been proposed
to reduce the risk of MAS by diluting the meconium,
thus reducing its mechanical and inﬂammatory eﬀects.
Amnioinfusion also helps by cushioning the umbilical cord,
thus correcting the recurrent umbilical compressions that
lead to fetal academia. In a meta-analysis of RCTs, Pierce
et al. [26] reported that intrapartum amnioinfusion was
signiﬁcantly associated with reduced risk of MAS (OR 0.30;
95% CI 0.19, 0.46), meconium below the vocal cords, and
neonatal acidemia.
In a recent Cochrane meta-analysis of 13 studies, the
author stratiﬁed the studies based on the clinical settings
[27]. Amnioinfusion reduces the risk of MAS only in
clinical settings with limited peripartum surveillance (RR
0.25, 95% CI 0.13 to 0.47), but not in clinical settings
with standard peripartum surveillance. However, American
College of Obstetricians and Gynecologists conclude that
routineprophylacticamnioinfusionforthedilutionofMSAF
is not recommended for the prevention of MAS [28].
5.1.4. Intrapartum Suctioning. In a large multicenter RCT
involving 2514 term infants with MSAF comparing intra-
partum suction versus no suction, the incidence of MAS (4%
versus 4%), mortality, the need of mechanical ventilation,
and duration of oxygen therapy were similar in both groups
[29]. Therefore, routine intrapartum oropharyngeal and
nasopharyngeal suctioning for infants born with clear or
meconium-stainedamnioticﬂuidisnolongerrecommended
[30].
5.1.5. Postpartum Endotracheal Suctioning. Neonatal resusci-
tation program (NRP) recommends intubation and direct
endotracheal suction soon after delivery for nonvigorous
infants born through MSAF, who have depressed respiratory
eﬀorts, poor muscle tone, and/or heart rate less than
100/minute [31]. Cochrane meta-analysis of four random-
ized studies did not show a diﬀerence in the incidence of
MAS between intubated and nonintubated vigorous infants
[32]. Hence, if the baby born through MSAF has a normal
respiratory eﬀort, normal muscle tone, and a heart rate
greater than 100 beats per minute, direct endotracheal
suction is not recommended. Only suctioning of mouth and
nose using a bulb syringe or large bore suction catheter
is indicated. According to the International Consensus on
Cardiopulmonary Resuscitation and Emergency Cardiovas-
cular Care Science, the available evidence does not support
or refute the routine endotracheal suctioning of depressed
infants born through MSAF [30].
5.2. Treatment of MAS. All infants at risk for MAS who
show signs of respiratory distress should be admitted in
the neonatal intensive care units. Close monitoring is
important since they can deteriorate very quickly. Once the
infant develops MAS, management is primarily supportive.
Maintenance of optimal thermal environment and minimal
handling is essential because these infants are agitated easily,
which causes right-to-left shunting, leading to hypoxia and
acidosis. Maintenance of adequate oxygenation, optimal
blood pressure, correction of acidosis, hypoglycemia and
other metabolic disorders is the mainstay of treatment.
5.2.1. Ventilation. Ventilator management of the neonate
with MAS is challenging because of the complicated pul-
monary pathophysiology resulting from areas of atelectasis
and areas of hyperinﬂation, in association with ventilation-
perfusion mismatch and airway compromise [33]. Approxi-
mately 40% of babies with MAS require mechanical ventila-
tion and additional 10% require continuous positive airway
pressure [34]. There is little evidence from the clinical trials
regarding the ventilator treatment of infants with MAS.
Ventilation should be aimed at increasing oxygenation
while minimizing the barotrauma that lead to air leak
syndromes. The amount of ventilator support depends on
severity of respiratory distress. Some infants only require
oxygen by hood. In infants with MAS who have hypoxemia
(PaO2 < 50mmHg), hypercarbia (PaCO2 > 60mmHg),
or acidosis (pH less than 7.25) in an oxygen-enriched
environment with an inspired oxygen fraction (FiO2) > 0.6
are often considered candidates for mechanical ventilation.
In infants with MAS without associated PPHN, it is
suﬃcient to maintain a pH of 7.3–7.4, with a PaO2 targeted
between 60 and 80mmHg and a PaCO2 of 40–50mmHg.
Infants may be started with a moderate peak inspiratory
pressure (PIP) preferably not exceeding 25cm H2O ,ar e l a -
tively rapid ventilator rate (40–60/min), a moderate positive
end expiratory pressure (4–6cm H2O), and an adequate
expiratory time (0.5–0.7sec) to prevent gas trapping and
air leaks. If gas trapping is noticed, expiratory time may be
increased and PEEP should be decreased (3-4cm H2O) [33].
In infants with MAS and concomitant PPHN, mild
hyperventilation and higher FiO2 can be considered. But the
strategy of achieving hypocapnia and alkalosis by hyperven-
tilation has adverse eﬀects including cerebral vasoconstric-
tion leading to long-term neurologic morbidity as well as
air leaks [35, 36]. In such situations other modalities like
inhaled nitric oxide and high frequency ventilation should
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Theoretically High Frequency Ventilation (HFV) mini-
mizes the barotrauma and may reduce air leak syndrome
in MAS. No prospective randomized trials have compared
conventional ventilation versus HFV in MAS. In pilot studies
using inhaled nitric oxide (iNO), Kinsella and Abman [37]
found that the combination of HFV and iNO caused the
greatest improvement in oxygenation in some patients with
severe PPHN. They speculated that improved lung inﬂation
duringHFVmayaugmenttheresponsetoiNObydecreasing
intrapulmonary shunting and improving iNO delivery to the
pulmonary circulation [37, 38]. Partial liquid ventilation was
found to be a better method of delivering surfactant in an
adult rat model of MAS when compared with conventional
mechanical ventilation [39]. There is no randomized clinical
trial about the use of partial liquid ventilation in human
neonates with MAS.
5.2.2. Surfactant Therapy. In vitro studies have shown that
meconium interferes with surfactant in several ways: inacti-
vation of its function depending on the concentration, direct
toxicity on type II pneumocytes, displacement of surfactant
from the alveolar surface, and decrease of surfactant protein
Aa n dBl e v e l s[ 2].
Canadian Pediatric Society position statement recom-
mends that intubated infants with MAS requiring more than
50% oxygen should receive exogenous surfactant therapy
[40]. Surfactant can be given as either a bolus therapy
or bronchoalveolar lavage. Bolus surfactant therapy for
MAS has been associated with reduction in the severity of
respiratory distress and decrease in the number of infants
with progressive respiratory failure requiring ECMO. Meta-
analysis of 4 RCTs showed reduction in the severity of
respiratoryillnessanddecreaseinthenumberofinfantswith
progressive respiratory failure requiring ECMO (RR 0.64,
95% CI 0.46–0.91) [41]. However, there was no signiﬁcant
diﬀerence in mortality, hospital stay, length of ventilation,
duration of oxygen use, pneumothorax, pulmonary intersti-
tial emphysema, or chronic lung disease.
Clinical trial of surfactant lavage using Lucinactant in
conventionally ventilated infants with MAS found no diﬀer-
ence between lavage infants and controls in terms of ECMO
requirements, air leak, or duration of ventilation [42].
Similarly, Dargaville and colleagues reported that lung lavage
with dilute surfactant (Survanta) in ventilated infants with
severe MAS does not decrease the duration of respiratory
support,butmayproduceareductioninmortality,especially
in units not oﬀering ECMO [43].
5.2.3. Role of Steroids. In 2003, Cochrane meta-analysis of
two trials [44, 45] including 85 infants with MAS showed
that there was no diﬀerence in mortality but a small
increase in the duration of oxygen treatment in steroid-
treated group [46]. Since then, two more trials reported that
steroid therapy in MAS was associated with a decrease in
the duration of oxygen therapy and hospital stay [47, 48].
The choice of steroid and duration of therapy was diﬀerent
betweenthestudies.SteroidsmaybebeneﬁcialinsevereMAS
with apparent lung edema, pulmonary vasoconstriction, and
inﬂammation. At present, there is no conclusive evidence to
propose routine steroid therapy in the management of MAS.
Further research is needed regarding the dosing, timing,
and ways of administration of steroids considering their
individual properties and possible acute and long-term side
eﬀects [49].
5.2.4. Role of Antibiotics. The presence of meconium in-
creases the chances of positive cultures from amniotic ﬂuid
in preterm and term infants. However, studies evaluating
the development of sepsis in infants with MSAF failed to
demonstrate that relationship [50]. Three randomized con-
trolstudiesreportedthatroutineantibioticprophylaxisisnot
recommended in the management of MAS for those without
perinatal risk factors [51–53]. Antibiotic therapy did not
aﬀect the clinical course and outcome related to infection in
MAS without perinatal risk factors for infection and without
ventilator use. The role of antibiotics in the management
of MAS may need to be reevaluated in well-designed trials.
Unless there is deﬁnite risk for infection, prophylactic use of
antibiotics in MAS did not reduce infection. If antibiotics are
started for suspected infection due to perinatal risk factors,
consider discontinuing antibiotics once the blood culture
results are negative.
5.2.5. Nitric Oxide. Severe MAS is often associated with
PPHN, resulting in severe hypoxemia. Randomized clinical
trials have demonstrated that iNO therapy decreases the
need for ECMO in addition to mortality in full-term and
near-term neonates with hypoxic respiratory failure and
PPHN [54]. For hypoxic respiratory failure due to MAS,
infants responded well to combined iNO and HFV as
compared to either treatment alone [55]. The response
to combined treatment with HFV and iNO reﬂects both
decreasedintrapulmonaryshuntandaugmentednitricoxide
delivery to its site of action.
5.2.6. Extracorporeal Membrane Oxygenation. ECMO has
been used as a ﬁnal rescue therapy in infants with severe and
refractory hypoxemia associated with MAS. Use of ECMO
has been decreased signiﬁcantly in developed countries with
the availability of iNO and HFV. Infants with MAS make
up approximately 35% of the infant population who require
ECMO[56].Thesurvivalratehasapproached95%ofinfants
with MAS who underwent ECMO [57]. In the ECMO
registry, the highest survival rates (>90%) were seen in the
patients with MAS who qualiﬁed for ECMO [58].
5.2.7. Adjunctive Therapies. All infants with MAS should
be monitored using noninvasive monitors (pulse oximeter,
transcutaneous O2/CO2 methods) and blood gas sampling
should preferably be done with an indwelling arterial line.
Sedation and analgesia are used frequently in infants with
MAS and PPHN to alleviate pain and discomfort that
may lead to hypoxia and right-to-left shunting. Opioids,
particularly morphine or fentanyl, are frequently used to
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catecholamine release, and aggravation of pulmonary vascu-
lar resistance.
Depolarizing muscle relaxants (pancuronium, vecuro-
nium) were widely used in the past along with opioids
to decrease agitation and subsequent hypoxic episodes in
ventilated infants. The beneﬁts of neuromuscular blockade
include improved oxygenation, decreased oxygen consump-
tion, and decreased accidental extubations. However, the
use of neuromuscular blockade remains controversial and is
reserved for the infant who cannot be treated with sedatives
alone. Neuromuscular blockage can promote atelectasis of
dependent lung regions and ventilation perfusion mismatch
and may also be associated with increased risk of death [59].
Nearly 30–50% of infants with PPHN do not respond
to iNO therapy. Infants who do not show initial response
to iNO and those that deteriorate subsequently while
on iNO therapy continue to have signiﬁcant PPHN and
need other alternative therapy [60]. Alternatives available
include (a) phosphodiesterase-5 inhibitors like Sildenaﬁl,
Zaprinast, Milrinone, dipyridamole, (b) prostaglandins like
Prostacyclin or PGE1, (c) tolazoline, Magnesium sulfate, (d)
NO precursor L-Arginine, (e) free radical scavengers like
Superoxide dismutase, (f) experimental agents like Bosentan
(endothelin antagonist).
5.2.8. Potential Future Therapy. Currently MAS treatments
are all supportive in nature and do not directly aﬀect the
injurious actions of meconium on the lung. There is still
no eﬀective and safe treatment or prophylactic measure for
MAS once the meconium has passed below the vocal cords
into the lungs. It has been suggested that fetal pancreatic
digestive enzymes play an important role in the lung
damage after meconium aspiration by causing disruption
of intercellular connections and cell detachment from the
basementmembrane.Aproteaseinhibitorcocktailprevented
the cell detachment induced by meconium suggesting that
they may be useful in the treatment and/or prophylaxis
[61]. Recent data show that some of the cell death induced
by meconium occurs by apoptosis, and therefore has the
potential for pharmacologic inhibition through the use of
apoptosis blockers or other strategies [62].
6. Conclusions
Despite improvement in obstetrical and neonatal care, MAS
continues to be a neonatal disorder with high morbidity and
mortality. The lung injury caused by meconium is complex
and can be attributed to mechanical obstruction of airways,
surfactant inactivation, chemical pneumonitis, and PPHN.
Among preventive strategies, elective induction of labor
for pregnancies at or beyond 41 weeks is associated with
signiﬁcant reduction in the incidence of MAS and amnioin-
fusion reduces the risk of MAS only in clinical settings with
limited peripartum surveillance. Intrapartum management
includes endotracheal suctioning to clear meconium only in
nonvigorous infants born through MSAF. The management
of a symptomatic infant with MAS is primarily supportive.
These infants are at high risk of developing PPHN and
air leaks. Invasive ventilation if required should use lower
PIP, moderate PEEP, higher rates (40–60/min), and adequate
expiratory time and permissive hypercapnea should be
tolerated to facilitate gentle ventilation. MAS complicated
with PPHN and not responsive to conventional ventilation
may require HFV and iNO. iNO therapy has decreased the
need for ECMO in MAS complicated by hypoxic respira-
tory failure and PPHN. Surfactant replacement should be
considered in ventilated infants requiring more than 50%
FiO2. Unless there is deﬁnite risk for infection, prophylactic
use of antibiotics in MAS does not reduce infection or alter
the clinical course of illness. ECMO has been used as a
ﬁnal rescue therapy in infants with severe and refractory
hypoxemia associated with MAS. The role of steroids and
other adjuvant pharmacotherapies like magnesium sulfate,
free radical scavengers, and protease inhibitors is still
experimental and they are not routinely recommended. As
MAS is a major cause of mortality in developing countries,
studies focusing on prevention and early treatment should
be continued to reduce mortality and morbidity.
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